Lv61
1730 积分 2023-03-06 加入
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
14天前
已完结
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
2个月前
已完结
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
3个月前
已完结
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
3个月前
已完结
How I Treat: Differentiation Therapy in Acute Myeloid Leukemia
3个月前
已完结
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
4个月前
已完结
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
4个月前
已关闭
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study
4个月前
已完结
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
4个月前
已完结
The future of HOXA-expressing leukemias: Menin inhibitor response and resistance
4个月前
已完结
皖公网安备34019202002308
